1832 Asset Management
GRCE

1832 Asset Management’s Grace Therapeutics GRCE Stock Holding History

1832 Asset Management’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-568
Closed -$69K – 719
2015
Q3 		$69K Buy
+568
New +$95.3K ﹤0.01% 488
2015
Q2 		– Sell
-353
Closed -$78K – 738
2015
Q1 		$78K Hold
353
– – ﹤0.01% 479
2014
Q4 		$85K Hold
353
– – ﹤0.01% 491
2014
Q3 		$122K Buy
+353
New +$166K ﹤0.01% 483

Other funds holding GRCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
EWM
Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CS
Credential Securities Vancouver $440M AUM 9.75% 1-Year Est. Return

1832 Asset Management's GRCE Position: Q4 2015 in Review

1832 Asset Management sold out of Grace Therapeutics (GRCE) in Q4 2015, closing a stake of 568 shares — an estimated $69K sold.

1832 Asset Management first reported a position in GRCE in Q3 2014 and held it in 4 quarters. The position peaked at $122K in Q3 2014. 12 funds tracked by Wall St. Rank hold GRCE as of Q4 2015.

  • 1832 Asset Management reported no remaining Grace Therapeutics position as of Q4 2015 after selling out during the quarter.
  • 1832 Asset Management sold 568 Grace Therapeutics shares in Q4 2015, an estimated $69K.
  • 1832 Asset Management first reported a position in Grace Therapeutics in Q3 2014 and held it in 4 quarters.
  • 1832 Asset Management's Grace Therapeutics position peaked at $122K in Q3 2014.
  • 12 funds tracked by Wall St. Rank held Grace Therapeutics as of Q4 2015.

Based on 1832 Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.